Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 6 for:    PIK3CA Related Overgrowth Spectrum

Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04285723
Recruitment Status : Not yet recruiting
First Posted : February 26, 2020
Last Update Posted : February 26, 2020
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:

The study is a site-based retrospective non-interventional medical chart review of pediatric and adult male and female patients with PIK3CA-Related Overgrowth Spectrum (PROS). Patient-level data are abstracted from medical charts of all eligible patients at all participating sites.

Information from patients treated with alpelisib will be used to describe the efficacy and safety of alpelisib in PROS patients.


Condition or disease
PIK3CA-Related Overgrowth Spectrum (PROS)

Layout table for study information
Study Type : Observational
Estimated Enrollment : 65 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Have Received Alpelisib as Part of a Compassionate Use Program (EPIK-P1)
Estimated Study Start Date : March 18, 2020
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : June 30, 2020

Resource links provided by the National Library of Medicine


Group/Cohort
alpelisib
Patients treated with alpelisib



Primary Outcome Measures :
  1. Proportion of patients with response (yes/no) at Week 24 (+/- 4 weeks) [ Time Frame: 24 weeks (+/- 4 weeks) ]
    Proportion of patients with response (yes/no) at Week 24 (+/- 4 weeks), defined by achieving at least 20% reduction from index date in the sum of measurable target lesion volume (1 to 3 lesions, via central review of imaging scans), provided that none of the individual target lesions have ≥ 20% increase from index date and in absence of progression of non-target lesions and without new lesions.


Secondary Outcome Measures :
  1. Percent change in the sum of measurable target lesion volume as measured by the change between the index date and key time-points following the index date [ Time Frame: 4, 12 , 24, 36, 52 weeks after starting the study treatment (index date) ]
    Percent change in the sum of measurable target lesion (1 to 3 lesions) volume, as assessed by a central review of imaging scans, as measured by the change between the index date (or up to 12 weeks prior) and key time-points following the index date

  2. Percent change in the sum of all measurable (target and non-target) lesion volume between the index date (or up to 12 weeks prior) and key time-points following the index date [ Time Frame: 4, 12 , 24, 36, 52 weeks after starting the study treatment (index date) ]
    Percent change in the sum of all measurable (target and non-target) lesion volume, as assessed by a central review of imaging scans, as measured by the change between the index date (or up to 12 weeks prior) and key time-points following the index date

  3. Description of medications and non-drug therapy received at key time points [ Time Frame: 4, 12 , 24, 36, 52 weeks after starting the study treatment (index date) ]

    Description of medications and non-drug therapy received at key time points

    • PROS-related treatment(s) other than alpelisib
    • Medication(s) (e.g., concomitant PROS-related medications including medication for the management of PROS related complications as well as medications to manage complications secondary to alpelisib)
    • Non-drug treatment(s) (e.g., feeding tube, ketogenic diet, non-invasive device for sleep apnea, sclerotherapy, endovascular occlusive procedures)
    • Alpelisib treatment (e.g., dose, dose adjustments, duration of treatment, dose interruptions, discontinuation)
    • PROS-related surgeries (e.g., de-bulking or vascular surgery as well as the intended site of the procedure)

  4. Change in PROS symptoms and complications over time [ Time Frame: 4, 12 , 24, 36, 52 weeks after starting the study treatment (index date) ]

    Change in PROS symptoms and complications over time

    • Overgrowth lesions, including number, girth, size, and color
    • Life-threatening complications (e.g., stroke, pulmonary embolism)
    • Chronic bleeding/leaking
    • Infection episodes
    • Hypotonia
    • Sleep disturbances
    • Seizures
    • Thrombotic events
    • Thromboembolic events
    • Pain
    • Cognitive impairment
    • Fatigue
    • Migraines
    • Depression/anxiety

  5. Change in functional status (work/school attendance) [ Time Frame: 4, 12 , 24, 36, 52 weeks after starting the study treatment (index date) ]

    Change in functional status

    o Work/school/pre-school attendance


  6. Change in health care resource use [ Time Frame: 4, 12 , 24, 36, 52 weeks after starting the study treatment (index date) ]

    7. Change in health care resource use

    • Non-medical resource use (e.g., physical therapy, occupational therapy, home care services)
    • Hospitalizations (including relevant medical interventions undertaken if related to PROS)
    • ER visits (including relevant medical interventions undertaken

  7. Change in laboratory assessments [ Time Frame: 4, 12 , 24, 36, 52 weeks after starting the study treatment (index date) ]
    Change in laboratory assessments (e.g., D-dimer, fibrinogen, hemoglobin, renal function, albumin, protein)

  8. Type, frequency, seriousness, and severity per CTCAE v4.03 criteria and causality assessments of treatment-emergent adverse events [ Time Frame: 4, 12 , 24, 36, 52 weeks after starting the study treatment (index date) ]

    Type, frequency, seriousness, and severity per CTCAE v4.03 criteria and causality assessments of treatment-emergent adverse events

    o Adverse events, including start and end date, grade, seriousness, relation to treatment, action taken with study treatment, and outcome


  9. Percent change in the sum of all measurable non-target lesion volume between the index date (or up to 12 weeks prior) and key time-points following the index date [ Time Frame: 4, 12, 24, 3, 52 weeks after starting the study treatment (index date) ]
    Percent change in the sum of all measurable non-target lesion volume, as assessed by a central review of imaging scans, as measured by the change between the index date (or up to 12 weeks prior) and key time-points following the index date

  10. Change in functional status (mobility) [ Time Frame: 4, 12 , 24, 36, 52 weeks after starting the study treatment (index date) ]

    Change in functional status

    o Mobility


  11. Change in functional status (performance status) [ Time Frame: 4, 12 , 24, 36, 52 weeks after starting the study treatment (index date) ]

    Change in functional status

    o Performance status


  12. Change in assessments of cardiac function [ Time Frame: 4, 12 , 24, 36, 52 weeks after starting the study treatment (index date) ]
    Change in cardiac assessments (e.g. ECG)

  13. Change in clinical assessments (height) [ Time Frame: 4, 12 , 24, 36, 52 weeks after starting the study treatment (index date) ]

    Change in clinical assessments

    o Vital signs (height)


  14. Change in clinical assessments (blood pressure) [ Time Frame: 4, 12 , 24, 36, 52 weeks after starting the study treatment (index date) ]

    Change in clinical assessments

    o Vital signs (blood pressure)


  15. Change in clinical assessments (weight) [ Time Frame: 4, 12 , 24, 36, 52 weeks after starting the study treatment (index date) ]

    Change in clinical assessments

    o Vital signs (weight)


  16. Change in clinical assessments (resting pulse) [ Time Frame: 4, 12 , 24, 36, 52 weeks after starting the study treatment (index date) ]

    Change in clinical assessments

    o Vital signs (resting pulse)




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients who participated in the compassionate use program and received alpelisib for the treatment of PIK3CA-related overgrowth spectrum (PROS).
Criteria

Inclusion Criteria:

  • Patient (adult or pediatric) is ≥ 2 years of age *
  • Patient has a physician confirmed/documented diagnosis of PROS*
  • Patient has a documented evidence of a mutation in the PIK3CA gene*
  • Patient's condition was assessed by the treating physician as severe or life threatening and treatment was deemed necessary*
  • Patient has been treated with at least one dose of alpelisib, initiated at least 24 weeks before the abstraction date, at a Novartis MAP site
  • Patient has medical chart history available during enrollment in the Novartis MAP
  • Patient (or parent/guardian in case of pediatric patient) consented to participate in the study (as required by local ethics regulations) * Inclusion criteria for MAP enrollment (assessed at the time of alpelisib initiation)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04285723


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals +41613241111 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals

Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04285723    
Other Study ID Numbers: CBYL719F12002
First Posted: February 26, 2020    Key Record Dates
Last Update Posted: February 26, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
alpelisib
PIK3CA
BYL719
PROS
Retrospective chart review study
EPIK-P1